Option Care Health (OPCH) has agreed to be acquired by Clayton Dubilier & Rice (CD&R) and McKesson Corp. (MCK) for $32.05 per share in cash, valuing the company at $5.8 billion. This deal represents a significant premium to OPCH's prior trading price and will result in the company being taken private, with McKesson holding a 49% stake and a path to acquire CD&R's majority stake later.
Option Care Health (OPCH) is being acquired by Clayton Dubilier & Rice and McKesson Corp. (MCK) for $32.05 per share, a 37% premium over its October 5th closing price. This is a major corporate catalyst for OPCH shareholders, offering a clear exit at a significantly higher valuation. For McKesson, this represents a strategic expansion into the home-infusion market, aligning with its long-term strategy to enhance access to innovative therapies. The current trading spread of $1.00 below the deal price suggests arbitrageurs anticipate a long closing timeline, potentially extending into the first half of 2027, due to regulatory approvals and a shareholder vote. This creates a modest annualized return opportunity for arbitrage traders, but also highlights the inherent risks of deal completion.